Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2012 Financial Results
Date:11/13/2012

WINSTON-SALEM, N.C., Nov. 13, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today reported its financial results for the third quarter ended September 30, 2012 and provided a business update.

"We are focused on enrolling the remaining four patients in the Phase 1 trial of our Neo-Urinary Conduit, which we hope to complete by year-end, and we are working aggressively to file the IND for our Neo-Kidney Augment during the first half of 2013," said John L. Miclot, President and Chief Executive Officer of Tengion. "We are dedicated to executing on our key program objectives and our successful $15 million private placement completed last month has provided us with sufficient funding to achieve these value creating milestones. We also recently received two Notices of Allowance from the USPTO for patent applications covering the novel technologies around the Neo-Urinary Conduit and Neo-Kidney Augment programs, which further solidify the breadth and strength of Tengion's novel technology and the expanding intellectual property portfolio around it."

Neo-Urinary Conduit Clinical Program UpdateTengion has implanted six patients in the ongoing Phase 1 clinical trial of its most advanced product candidate, the Neo-Urinary Conduit, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). The trial is an open-label, single-arm study, which is expected to enroll up to 10 patients.

In November 2012, Tengion announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 12/612,606, titled "Cell-Scaffold Constructs." The application includes compositional claims on the construct and cellular elements of the Neo-Urinary Conduit, as well as use claims covering this technology in additional clinical applications.

In October 2012, Tengion announced that two patients in the Phase 1 clinical trial of its Neo-
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
2. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
3. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. New Resource Provides Herb Industry With Sources of Quality Specifications
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
8. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
9. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
10. Insmed Incorporated Provides Corporate Update
11. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 GliaCure, a privately-held biotechnology company ... neurological and neuropsychiatric disorders based on glial targets, ... patients in a Phase 1b clinical trial of ... as a potential disease-modifying treatment. GliaCure,s innovative approach ... it both promotes the clearance of amyloid and ...
(Date:5/4/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Dr. Roger J Garceau, to its Board of ... matters including corporate development and clinical strategy, his ... regulatory expertise as Fluorinov transitions to clinical development.  ... of pharmaceutical development experience to Fluorinov and most ...
(Date:5/4/2015)... May 04, 2015 Genedata, a ... discovery and life science research, today announced the ... latest version of its enterprise solution for biologics ... enables more efficient discovery and development of novel ... integrate and address protein optimization and developability requirements. ...
(Date:5/4/2015)... May 4, 2015 China Cord Blood Corporation ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... a Hong Kong listed company ... into an agreement (the "Agreement") to purchase the Company,s ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... the Middle Class Using India,s Private Health Care System, ... be an Increasing Need for Diagnostic Imaging Equipment, ... that growing demand for private health care in India ... a result, the,market will experience rapid growth, reaching a ...
... Ventures, Khosla Ventures, Kleiner Perkins ... and TPG Ventures, Strong Endorsement of Technology Pioneer at Forefront of Developing ... ... development of renewable hydrocarbon biofuels, today,announced that it closed the first tranche of ...
... ,Arpida Ltd (SWX: ARPN) was invited to present ... antimicrobial agents at the 47th annual,Interscience Conference on ... a major scientific conference where thousands of,scientists and ... discuss the,latest developments in the field of infectious ...
Cached Biology Technology:Not Just for the Rich: India's Private Health Care is Booming 2Amyris Biotechnologies Announces $70 Million Series B Round 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... If that office inkjet printer has become just another ... Similar technology may soon be used to develop paper-based ... food poisoning or be used as bioterrorism agents. In ... Chemistry , John Brennan and his research team at McMaster ...
... The destructive cellular pathways activated in Alzheimer,s disease ... researchers from Georgetown University Medical Center (GUMC). They ... successfully target both conditions. In an oral ... on Alzheimer,s Disease, the scientists will show that ...
... June 22 The Federal Bureau of Investigation (FBI) ... a five-year, $47 million contract to continue managing the ... Service (CSS) program. The contract covers the conversion of ... electronic records for the FBI. , , ...
Cached Biology News:Toxin detection as close as an inkjet printer 2Alzheimer's disease drug treats traumatic brain injury, report GUMC researchers 2Federal Bureau of Investigation Awards Lockheed Martin Biometric Card Scanning Service Contract 2
... JASCO HPLC systems. , Integrated Instrument Control , ... EZChrom Elite can be configured ... systems. This provides a completely integrated system to control instrument's operation, ... , ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... Mass Spectrometry Applications ,In the age ... emerged as a powerful protein identification and ... is now an important intermediate step in ... to identification of specific proteins in the ...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
Biology Products: